These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 25808896)

  • 1. Improvement of Depression and Anxiety After Discontinuation of Long- Term Efavirenz Treatment.
    Mothapo KM; Schellekens A; van Crevel R; Keuter M; Grintjes-Huisman K; Koopmans P; van der Ven A
    CNS Neurol Disord Drug Targets; 2015; 14(6):811-8. PubMed ID: 25808896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s).
    Clifford DB; Evans S; Yang Y; Acosta EP; Ribaudo H; Gulick RM;
    HIV Clin Trials; 2009; 10(6):343-55. PubMed ID: 20133265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychiatric symptoms in Tanzanian HIV-infected children receiving long-term efavirenz treatment: a multicentre, cross-sectional, observational study.
    Van de Wijer L; Mchaile DN; de Mast Q; Mmbaga BT; Rommelse NNJ; Duinmaijer A; van der Ven AJAM; Schellekens AFA; Kinabo GD
    Lancet HIV; 2019 Apr; 6(4):e250-e258. PubMed ID: 30770324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efavirenz is related to neuropsychiatric symptoms among adults, but not among adolescents living with human immunodeficiency virus in Kilimanjaro, Tanzania.
    Sumari-de Boer M; Schellekens A; Duinmaijer A; Lalashowi JM; Swai HJ; de Mast Q; van der Ven A; Kinabo G
    Trop Med Int Health; 2018 Feb; 23(2):164-172. PubMed ID: 29220120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Better health-related quality of life after switching from a virologically effective regimen to a regimen containing efavirenz or nevirapine.
    Potard V; Chassany O; Lavignon M; Costagliola D; Spire B
    AIDS Care; 2010 Jan; 22(1):54-61. PubMed ID: 20390481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study.
    Pedrol E; Llibre JM; Tasias M; Currán A; Guardiola JM; Deig E; Guelar A; Martínez-Madrid O; Tikhomirova L; Ramírez R;
    HIV Med; 2015 Nov; 16(10):628-34. PubMed ID: 26238151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial.
    Dabaghzadeh F; Ghaeli P; Khalili H; Alimadadi A; Jafari S; Akhondzadeh S; Khazaeipour Z
    AIDS Patient Care STDS; 2013 Mar; 27(3):146-54. PubMed ID: 23442031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of dizziness in human immunodeficiency virus-infected patients taking zidovudine and efavirenz combination: a Brazilian cohort study.
    Valeriano JJLS; Carvalho-Silva WHV; Coelho AVC; Moura RR; Arraes LC; Brandão LAC; Crovella S; Guimarães RL
    J Pharm Pharmacol; 2020 May; 72(5):719-727. PubMed ID: 32043598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depression is associated with efavirenz-containing treatments in newly antiretroviral therapy initiated HIV patients in Ecuador.
    Checa A; Castillo A; Camacho M; Tapia W; Hernandez I; Teran E
    AIDS Res Ther; 2020 Jul; 17(1):47. PubMed ID: 32727488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial.
    Gutiérrez-Valencia A; Viciana P; Palacios R; Ruiz-Valderas R; Lozano F; Terrón A; Rivero A; López-Cortés LF;
    Ann Intern Med; 2009 Aug; 151(3):149-56. PubMed ID: 19581631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired sperm motility in HIV-infected men: an unexpected adverse effect of efavirenz?
    Frapsauce C; Grabar S; Leruez-Ville M; Launay O; Sogni P; Gayet V; Viard JP; De Almeida M; Jouannet P; Dulioust E
    Hum Reprod; 2015 Aug; 30(8):1797-806. PubMed ID: 26085581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.
    Clifford DB; Evans S; Yang Y; Acosta EP; Goodkin K; Tashima K; Simpson D; Dorfman D; Ribaudo H; Gulick RM
    Ann Intern Med; 2005 Nov; 143(10):714-21. PubMed ID: 16287792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.
    Muñoz-Moreno JA; Fumaz CR; Ferrer MJ; González-García M; Moltó J; Negredo E; Clotet B
    AIDS Rev; 2009; 11(2):103-9. PubMed ID: 19529750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability of central nervous system symptoms among HIV-1 infected efavirenz users: analysis of patient electronic medical record data.
    Rosenblatt L; Broder MS; Bentley TGK; Chang E; Reddy SR; Papoyan E; Myers J
    AIDS Care; 2017 Aug; 29(8):1067-1073. PubMed ID: 28147708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Discontinuation of Efavirenz as Treatment for HIV, Due to Neuropsychiatric Side Effects, in a Multi-Ethnic Sample in the United Kingdom.
    Law JKC; Butler LT; Hamill MM
    AIDS Res Hum Retroviruses; 2020 Jun; 36(6):459-466. PubMed ID: 31931589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.
    Leutscher PD; Stecher C; Storgaard M; Larsen CS
    Scand J Infect Dis; 2013 Aug; 45(8):645-51. PubMed ID: 23427878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications.
    Gaida R; Truter I; Grobler C; Kotze T; Godman B
    Expert Rev Anti Infect Ther; 2016; 14(4):377-88. PubMed ID: 26900637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz.
    Blanch J; Martínez E; Rousaud A; Blanco JL; García-Viejo MA; Peri JM; Mallolas J; De Lazzari E; De Pablo J; Gatell JM
    J Acquir Immune Defic Syndr; 2001 Aug; 27(4):336-43. PubMed ID: 11468421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Valerian in Preventing Neuropsychiatric Adverse Effects of Efavirenz in HIV-Positive Patients: A Pilot Randomized, Placebo-Controlled Clinical Trial.
    Ahmadi M; Khalili H; Abbasian L; Ghaeli P
    Ann Pharmacother; 2017 Jun; 51(6):457-464. PubMed ID: 28478716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.